MYC is an important oncogene in hematopoietic neoplasms in humans, yet the mechanism by which MYC induces the malignant transformation of blood cells has remained elusive. Postulating that mouse models of deregulated MYC expression may be helpful for advancing our understanding of MYC-induced hematopoietic malignancies, Suzanne Cory and her associates took advantage of the Vav promoter to express MYC throughout the hematopoietic system in transgenic mice. In this issue of Oncogene, they report (Smith et al.) that the newly developed strain, referred to as VavP-MYC17, is prone to mature T-cell lymphomas (for which few good mouse models exist). They further show that VavP-MYC17 mice that are devoid of mature T cells (and B cells) because of genetic deficiency in Rag1 recombinase develop neoplasms of three distinct blood cell lineages: pre-T cells, pro-B cells, and macrophages. These findings establish that VavP-driven MYC has broad oncogenic potential in the hematopoietic compartment and prompts new views of the cellular assaults of deregulated MYC on hematopoietic stem and early progenitor cells. Mouse models of deregulated MYC expression have been crucial for advancing our understanding of MYCinduced neoplasia. One of the first and most successful models of this sort was developed 20 years ago by a research group including Suzanne Cory at the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia. They showed that transgenic MYC under control of the immunoglobulin heavy-chain Em enhancer predictably caused malignant B-cell tumors in mice (Adams et al., 1985) . It is difficult to overestimate the impact that the Em-MYC mouse model had on the research community concerned with mechanisms of B-cell and plasma cell neoplasms. Strain Em-MYC was embraced by several key investigators who focused their investigations on MYC-dependent apoptosis, oncogenes and tumor suppressor genes that collaborate with MYC in neoplastic development, cellular pathways that determine the susceptibility of MYC-driven tumors to chemotherapeutic agents, and many other aspects of MYC function. However, analogous to countless cell lineage-specific transgenes that have been developed in the past decades, the insights gleaned from the Em-MYC model were limited to one cell lineage: B-lymphocytes. Now a study from Suzanne Cory's group published in this issue of Oncogene (Smith et al.) overcomes the limitations of lineage specificity of transgenic MYC. Using a clever approach for expressing MYC broadly throughout the hematopoietic system, the authors uncovered new cellular targets of MYC's oncogenic activity.
To explore the oncogenic potential of MYC in a wide variety of hematopoietic cells, Suzanne Cory and her associates took advantage of a previously developed Vav expression cassette (Ogilvy et al., 1999) and developed a new transgenic mouse strain referred to as VavP-MYC17. In this strain, MYC is driven by the promoter of mouse Vav, which is expressed throughout the hematopoietic compartment (Ogilvy et al., 1998) . In the present Oncogene paper, Smith et al. report that young, tumor-free VavP-MYC17 mice exhibit multiple hematopoietic abnormalities affecting B cells, monocytes, and megakaryocytes, leading them to expect that these mice will go on to develop a diversity of neoplasms derived from these three cell types. To their surprise, they observed, instead, that the mice developed exclusively T-cell lymphomas, mostly of the mature CD4 þ CD8 À phenotype, for which few good mouse models exist (Figure 1, yellow box) . This finding indicated that, for reasons that are currently unknown, mature T cells are the most susceptible targets of VavP-MYC17-driven tumor development.
The rapidly arising T-cell tumors may have obscured additional MYC targets in the hematopoietic system. To evaluate this hypothesis, Smith et al. bred the VavP-MYC17 mice onto the background of Rag1 deficiency. Mice that lack the Rag1 recombinase are unable to undergo V(D)J recombination and exhibit, therefore, a complete block in the development of mature T and B cells. Rag1-deficient VavP-MYC17 mice survived longer than their Rag1-proficient counterparts, but succumbed eventually to neoplasms of three distinct blood cell lineages: pre-T cells, pro-B cells, and macrophages (Figure 1, black box) . This result showed that the VavP-MYC17 transgene is capable of transforming alternative cellular targets when the primary target (T cells) is removed. It further established strain VavP-MYC17 as a new model of MYC-induced neoplasms of multiple hemopoietic lineages.
Of great additional interest is the occurrence of novel neoplasms in VavP-MYC17 Rag1
À/À mice that express high levels of Thy1 (T-cell marker), B220 (B-cell marker), and Gr1 and F4/80 (myeloid markers). This surface marker profile corresponds to the differentiation potential of the common myelolymphoid progenitor (CMLP), but has no known counterpart in normal hematopoiesis. The phenotype of these tumors is different from the Thy1 þ B220 þ lymphomas that were previously detected by Cory and co-workers in doubly transgenic Em-Myc/Em-Bcl2 mice (Strasser et al., 1990) . These bi-lineage lymphomas are presumptive counterparts of the bi-potential (T and B cells) common lymphoid progenitor (CLP). The unique phenotype of the present tri-lineage Thy1
þ tumors suggests that the VavP-MYC17 transgene is capable of transforming an immediate, lineal progenitor of the hematopoietic stem cell (HSC).
A related study published last year by Dr Cory and her collaborators in Blood used the same Vav promoter/ enhancer construct to drive the expression of the death suppressor Bcl2 in blood cells (Egle et al., 2004) . In a remarkable parallel to the mature T-cell lymphomas that arose in strain VavP-MYC17, the VavP-Bcl2 transgenic mice developed predominantly tumors of mature postgerminal center B cells: follicular B-cell lymphomas (Figure 1, purple box) . Just like for mature T-cell lymphomas, good mouse models of mature B-cell lymphomas are scarce. Although the VavP-Bcl2 mice have not yet been bred onto a Rag-deficient background, the experience with the VavP-MYC17 would suggest that this results in a spectrum of immature B-cell tumors, perhaps including novel tumors with bi-or multilineage differentiation potential.
As with all good studies, the present Oncogene paper raises many new questions. Among these: what is the reason for the absence of erythroid, megakaryocytoid, and stem cell tumors in the VavP-MYC17 mice? Is VavP-directed expression of MYC insufficient to cause neoplastic transformation of pluripotent stem cells and some of their direct lineal descendants, such as the common erythroid-megakaryocyte progenitor (CEMP) or the CMLP that is committed to the granlulocytic lineage? Or are these cell types simply more resistant to MYC-induced transformation compared to CMLP that are committed to the monocyte-lymphocyte maturation pathway? A related problem is whether the enforced expression of MYC in stem cells changes the balance between self-renewal and differentiation of these cells and/or the biology of early progenitors with attendant alterations in their lineage fidelity.
The observation that VavP-driven MYC has broad oncogenic potential in the hematopoietic compartment significantly advances our appreciation of MYC's transformation-inducing potential in blood cells. It also prompts new views of the cellular assaults of deregulated MYC on hematopoietic stem and early progenitor cells. The VavP-MYC17 mice no doubt hold great promise to become as useful as their famous Em-MYC predecessors. 
